2 citations
,
September 2024 in “Journal of the American Academy of Dermatology” Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.
26 citations
,
June 2010 in “Acta Pharmaceutica” Methods accurately measure tamsulosin hydrochloride and finasteride in combined dosages.
2 citations
,
July 2025 in “Analytical Chemistry” The method effectively images and correlates elements and metabolites in tissue samples at a micron scale.
January 2019 in “Analytical Science and Technology” About 21% of tested hair loss supplements contained illegal synthetic drugs.
February 2026 in “Chromatographia” A reliable method was developed to detect hair growth compounds in products, ensuring safety and compliance.
3 citations
,
January 2006 in “Eclética Química” Three cost-effective methods accurately measure finasteride in pharmaceuticals, better than current techniques.
January 2006 in “OpenMETU (Middle East Technical University)” The same drug is priced differently based on its use.
November 1968 in “Journal of the American Pharmaceutical Association”
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
July 2023 in “International Journal of Molecular Biology and Biochemistry” The hair oil made with Arnica montana, castor, and mustard oils is effective.
January 2026 in “Open Science Framework” Biochanin A from soy is a promising and safe candidate for treating hair loss.
Different amounts of propylene glycol change the thickness of katuk leaf hair tonic.
March 2005 in “Journal of the American Academy of Dermatology” Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.
November 2023 in “International Journal of Pharmaceutics” The new delivery system improves treatment for hair loss by enhancing drug absorption and effectiveness.
1 citations
,
November 2020 in “Journal of the American Academy of Dermatology” Most sunscreens meet safety standards, but tanning products often don't.
November 2025 in “Urology” CPDC offers significant cost savings on men's health medications compared to Medicare and GoodRx.
September 2016 in “Toxicology letters” The 5050 MHA42MCS45 hydrogel blend is suitable for repairing load-bearing soft tissues.
45 citations
,
June 2008 in “Journal of pharmaceutical and biomedical analysis” The method effectively identifies banned substances in hair loss and skin disease cosmetics.
September 2018 in “Value in Health” Orphan drug benefit scores in Germany are influenced by phase III data and lack of alternatives, but not linked to price or discounts.
5 citations
,
January 2014 in “Asian Journal of Chemistry” Researchers developed a quick and reliable method to test for betamethasone dipropionate and calcipotriol in ointments and drugs.
4 citations
,
January 2025 in “Pharmaceutics” The gel is a safe and effective treatment for hyperpigmentation.
4 citations
,
October 2015 in “Journal of Evaluation in Clinical Practice” European guideline best for treating hair loss; involve stakeholders and patients for improvement.
May 2026 in “Journal of Drugs in Dermatology” The dual-serum cosmetic system effectively improves hair loss in women.
May 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Biochanin A from soy is a promising and safe candidate for treating hair loss.
November 2022 in “The Journal of Urology” Adopting the Mark Cuban Cost Plus Drug Company pricing model could save Medicare about $1.29 billion on urological drugs.
7 citations
,
October 2019 in “Brazilian Journal of Petroleum and Gas” The microemulsion-based fluid effectively removes mud cake during well cementation.
March 2026 in “Zenodo (CERN European Organization for Nuclear Research)” The herbal trio pack of shampoo, conditioner, and serum promotes hair health with minimal side effects.
Betamethasone dipropionate lotion is more effective than minoxidil solution for treating Alopecia Areata.
July 2007 in “Journal of Generic Medicines” The UK High Court revoked Lundbeck's patent for Escitalopram, and second medical use claims based on dosage were not considered novel.
July 2024 in “Reactions Weekly”